Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA dgolds8@emory.edu.
Daniel A
DA
Goldstein
Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Bassel F
BF
El-Rayes
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000473:pathology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic; D014481:United States; D000096662:Ramucirumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002166:Camptothecin; D005472:Fluorouracil; D002955:Leucovorin; D000096662:Ramucirumab